This poster evaluates patient characteristics and 3-month outcomes in patients prescribed alternate-dose biologic therapy. Of 220 patients, one-third were previous/current smokers, and 40% had a psychiatric comorbidity. Median disease duration was 11 years (IQR 6-18), 46% previously underwent surgery.

This study evaluated access and affordability of HIV PrEP in patients seen at a multidisciplinary PrEP clinic. In this cohort of mostly commercially insured men, the majority were able to access PrEP with low out-of-pocket costs facilitated by manufacturer assistance. Although generalizability beyond this population is limited, these results contradict perceived financial barriers to PrEP access.

In the Southern US, HIV prevalence is disproportionately high and PrEP use is disproportionately low. This cross-sectional survey study assessed Tennessee primary care providers’ current PrEP knowledge, attitudes, and prescribing practices with the aim to determine barriers to PrEP provision specific to TN providers.

The purpose of this study was to explore student education about HIV and related topics using a cross-sectional, population-based survey of U.S. pharmacy schools with a 15-item questionnaire. We found diversity in the amount of time devoted to HIV didactic education among the 37 U.S. pharmacy schools who completed the survey, with some schools providing minimal didactic teaching on the topic of HIV along with low rates of exposure to PLWH in experiential training.

The obejctive of the poster is to describe PrEP medication adhernece and persistence in patients seens at a multidisciplinary PrEP clinic. Patients receiving PrEP in a multidisciplinary clinic with an integrated clinical pharmacist had high rates of adherence and persistene. Patients reported few side effects and reasons for discontinuation were appropriate.

While historical treatments combining interferon and ribavirin were less efficacious in HIV/HCV coinfection, modern direct-acting antiviral (DAA) therapies have shown similar clinical efficacy in HIV/HCV coinfection as in HCV monoinfection. In light of these findings, HIV/HCVcoinfected patients may benefit even more from new HCV treatment approaches. This article reviews the many therapeutic options for HIV/HCV coinfected patients with emphasis on avoiding drug-drug interactions.

This study was among the first to evaluate patient outcomes to all-oral, sofosbuvir (SOF)-based, HCV therapies in a real world setting and assess the impact of a clinic-integrated specialty pharmacy on therapy completion. We found higher completion rates in patients filling through VSP (97%) compared to outside pharmacies (93%), and a 100% medication access rate.

This study demonstrated the benefits of pharmacist integration into an interdisciplinary to treatment patients with chronic HCV. Pharmacist integration resulted in improved patient engagement, reduced provider burden, and increased rate of HCV treatment.

Prior to the release of sofosbuvir/velpatasvir/voxilaprevir, few options for retreating patients failing HCV direct acting antiviral (DAA) therapy. This study evaluated the effectiveness of sofosbuvir + simeprevir + ribavirin for 24 weeks in retreating patients who previously failed HCV treatment containing an NS5A inhibitor.

This study describes a real world cohort of HIV/HCV co-infected patients in an outpatient infectious diseases clinic with a focus on the frequency and impact of HIV antiretroviral adjustments required prior to HCV direct acting antiviral initiation.